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The Breakthrough Balloon
for Critical Limb Ischemia?*
Michael R. Jaff, DO
Boston, Massachusetts
A true medical breakthrough represents “a sudden advance
especially in knowledge or technique” (1). In the field of
vascular medicine, such a breakthrough is welcome, because
many of the treatments we have for peripheral artery disease
(PAD) are limited. Of the patients with PAD, the subgroup
with the highest risk of limb loss and mortality are those with
critical limb ischemia (CLI) (ischemic rest pain, nonhealing
ischemic ulcerations, gangrene). With the explosive epidemic
of diabetes mellitus, it is likely that the prevalence of CLI will
increase as well in years to come (2). Historically, the standard
treatment of CLI has been complex surgical reconstruction
using autologous saphenous vein from a proximal inflow artery
to a healthy distal target artery, often located in the distal calf
or foot. Despite excellent technical results with acceptable limb
salvage rates, patient comorbidities often result in serious
postoperative complications, including incisional infection,
myocardial infarction, stroke, and death.
See page 1105
In a meta-analysis of distal surgical bypass grafts among
patients with CLI performed at centers with expertise in such
revascularization procedures, the limb salvage rate was 78% (3).
owever, among such patients, 25% wound complication rates
ere reported (4). Perhaps the most sobering of statistics
mong patients with CLI is the dramatic reduction in survival.
he Transatlantic Intersociety Consensus for the Manage-
ent of Peripheral Arterial Disease reports that 20% of patients
ie within the first year of seeking treatment for CLI (5).
Primary medical therapy, particularly for patients at prohib-
tive risk of serious complications with surgery, or without a
uitable revascularization option, is very limited. Although
ome investigators have suggested that spinal cord stimulation
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organization).s an effective alternative among patients without a suitable
evascularization option, a recent review of the published
iterature has demonstrated no real usefulness in these patients
6). With the recent lack of evidence of efficacy using angio-
enesis therapy (7), investigators have demonstrated interest in
tem cell and progenitor cell therapy (8) as future options for
atients with nonrevascularizable PAD and CLI.
Given the mortality rates and complications associated
ith surgical revascularization, many clinicians have sug-
ested that endovascular therapy is a safer and equally
ffective alternative. Primary revascularization using percu-
aneous transluminal angioplasty (PTA) for CLI has been
eported in multiple single-center observations (9). As
atient selection and technology have become more sophis-
icated, results have improved, with a recent meta-analysis
emonstrating 82.4% limb salvage rates at 3 years (10).
The most important modern randomized study of surgical
evascularization compared with PTA is the BASIL (Bypass
ersus Angioplasty in Severe Ischaemia of the Leg) trial. In a
nal report of the primary intention-to-treat outcome, rates of
mputation-free survival and overall survival were no different
etween the 2 treatments. However, among patients who
urvived at least 2 years after randomization, those patients
reated with surgical revascularization lived 7 months longer
11). This study raises further confusion regarding the optimal
trategy for patients with CLI. Varu et al. (12) suggest that
urgical revascularization should be the principal revasculariza-
ion strategy among patients with more diffuse infrapopliteal
isease, whereas others suggest that advances in technology
ave expanded the population of patients with CLI who would
e best treated with PTA (13).
Schmidt et al. (14) have distinguished themselves as among
he most prolific of clinical vascular researchers of the modern
ra, and their contribution to this issue of the Journal is no
xception. The authors demonstrated, for the first time, im-
ressive results of endovascular intervention using an angio-
lasty balloon coated with paclitaxel and a novel spacer, urea.
lthough there have been preliminary reports of the efficacy of
rug-coated balloons in PAD (15), this particular study dem-
nstrated impressive results with much longer anatomic lesions
n the most challenging of arterial beds, the infrapopliteal
rteries. In this single-center series of 104 patients and 109
imbs enrolled over 13 months, 82.6% had CLI at presentation
approximately 65% with minor or major tissue loss). The
emographics of the study population highlight the major
omorbidities associated with CLI: 71% with diabetes mellitus,
6% with chronic kidney disease, and 46% with coronary artery
isease. The mean lesion length was 17.3 mm.
At 3 months, angiography performed on 74 patients (79
imbs) demonstrated primary patency of 72.6%. Of those
ith restenosis, complete reocclusion developed in 8.3%,
hereas the remainder demonstrated more focal stenosis.
he authors previously defined a much higher restenosis
ate with PTA balloons without drug coating of almost 70%
t 3 months in lesions of similar lengths (16).
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salvage rate of patients with CLI was 95.6%. Of patients with
ischemic ulcerations at baseline, 74.2% of these ulcerations
healed completely at a mean follow up of 378  65 days.
Despite these impressive findings, this study is limited by
the single-center nature of the evaluation and the potential
for selection bias by the investigators for patients whose
anatomical features may be optimally suited for this specific
intervention. Future prospective nonrandomized evalua-
tions of specific endovascular treatments for patients with
CLI should include major adverse limb events and mortality
rates (17). However, the U.S. Food and Drug Administra-
tion commented that “certain novel device types, such as
drug-device combination products may not be suitable for
evaluation in a single arm study because historical data may
not represent an adequate comparator due to technology
and clinical practice. Randomized controlled trials may be
necessary to evaluate these types of products” (18). There-
fore, future trials of drug-coated balloons should be per-
formed in prospective, randomized fashion.
The authors identify 2 arteries in which ectasia developed
during angiographic follow-up. Despite their reassurance,
the concepts describing the mechanisms and impact of drug
delivery by an angioplasty balloon catheter are still in their
infancy, and this finding raises some concern. Future inves-
tigations will need to study the impact of this therapy on
arterial wall integrity over time.
Finally, the cost of this specific technology must be greater
than so-called bare balloon catheters. If the clinical indication
for use of drug-coated balloons is limb salvage via healing of
ischemic ulcerations, it seems that despite the marked im-
provement in vessel patency, there is no clear advantage of the
more expensive technology over PTA alone. The authors
highlight the potential advantage that drug-coated balloons
require fewer repeat interventions when compared with PTA,
and this may result in a cost advantage of this technology.
Formal cost-effectiveness analyses will be required to demon-
strate the advantages of one therapy over the other; however,
one must question whether costs will favor this technology in
the era of healthcare reform.
Of greatest impact, however, is the reported mortality rate of
16.3% among 104 patients included in this study at 12 months.
This mortality is significantly higher than that for women with
breast cancer (e.g., 24 per 100,000 women/year) (19), and
underscores the importance of comprehensive attention to the
identification and modification of atherosclerotic risk factors
and established arterial diseases in other vascular beds (i.e.,
coronary, cerebrovascular). For any endovascular technology to
represent a true breakthrough, not only must the treatment
promote improvement in functional capacity and limb salvage,
but also strategies to prolong overall survival must be even more
effective. Without the latter, the relevance of patent limb
arteries wanes.Reprint requests and correspondence: Dr. Michael R. Jaff,
Massachusetts General Hospital, 55 Fruit Street, Boston, Massa-
chusetts 02114. E-mail: mjaff@partners.org.
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